506725793 06/21/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6772611

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
JANSSEN PHARMACEUTICA NV	01/20/2016

RECEIVING PARTY DATA

Name:	JANSSEN SCIENCES IRELAND UC	
Street Address:	EASTGATE VILLAGE, LITTLE ISLAND	
City:	CO CORK	
State/Country:	IRELAND	

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	16071649
Application Number:	16840279

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2693377838

Email: patents@honigman.com
Correspondent Name: ANDREW WEBER

Address Line 1: 650 TRADE CENTRE WAY SUITE 200
Address Line 4: KALAMAZOO, MICHIGAN 49002-0402

ATTORNEY DOCKET NUMBER:	268041-488391/488392	
NAME OF SUBMITTER:	ANDREW N. WEBER	
SIGNATURE:	/Andrew N. Weber/	
DATE SIGNED:	06/21/2021	

Total Attachments: 1

source=3-Janssen NV to Janssen UC#page1.tif

PATENT 506725793 REEL: 056605 FRAME: 0184

General Assignment

WHEREAS, Janssen Pharmaceutica NV having its place of business at Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"Ary! substituted pyrimidines for use in influenza virus infection"

for which on the 20th day of January 2016, European Patent Application no. 16152095.2 was filed at the European Patent Office.

WHEREAS, Janssen Sciences Ireland UC, having its place of business at Eastgate Village, Eastgate, Little Island, Co Cork, Ireland (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 20th day of January 2016.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen Pharmaceutica NV

For Janssen Sciences Ireland UC

Luc Quaghebeur, Authorized Signatory

For Janssen Pharmaceutica NV

Frank Daelemans, Authorized Signatory For Janssen Sciences Ireland UC

> PATENT REEL: 056605 FRAME: 0185

RECORDED: 06/21/2021